Mobile

A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIE...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000937-37

A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety of a tacrolimus modified release, MR4, based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg : mg) basis from a Prograf based immunosuppressive regimen. Non-inferiority for creatinine clearance will be assessed.

Critère d'inclusion

  • Stable, adult kidney transplant recipients (≥ 12 months post transplant) who are currently treated with Prograf

Liens